These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33123544)

  • 21. Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta-Analysis.
    Alkofide H; Almohaizeie A; Almuhaini S; Alotaibi B; Alkharfy KM
    Int J Infect Dis; 2021 Sep; 110():320-329. PubMed ID: 34273515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of tocilizumab therapy in severe or critical COVID-19 patients: A retrospective cohort, single-centre study.
    Abdelnaby H; Aboelhassan W; Al-Jarallah M; Rajan R; Dashti R; Zhanna KD; Alsaber AR; Abd El-Aleem A; Ashry I; Abdullah M; Mahmoud Fouad A
    Trop Med Int Health; 2021 Dec; 26(12):1689-1699. PubMed ID: 34601803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis.
    Conti V; Corbi G; Sellitto C; Sabbatino F; Maci C; Bertini N; De Bellis E; Iuliano A; Davinelli S; Pagliano P; Filippelli A
    J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis.
    Berardicurti O; Ruscitti P; Ursini F; D'Andrea S; Ciaffi J; Meliconi R; Iagnocco A; Cipriani P; Giacomelli R
    Clin Exp Rheumatol; 2020; 38(6):1247-1254. PubMed ID: 33275094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
    Ghosn L; Assi R; Evrenoglou T; Buckley BS; Henschke N; Probyn K; Riveros C; Davidson M; Graña C; Bonnet H; Jarde A; Ávila C; Nejstgaard CH; Menon S; Ferrand G; Kapp P; Breuer C; Schmucker C; Sguassero Y; Nguyen TV; Devane D; Meerpohl JJ; Rada G; Hróbjartsson A; Grasselli G; Tovey D; Ravaud P; Chaimani A; Boutron I
    Cochrane Database Syst Rev; 2023 Jun; 6(6):CD013881. PubMed ID: 37260086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies.
    Maraolo AE; Crispo A; Piezzo M; Di Gennaro P; Vitale MG; Mallardo D; Ametrano L; Celentano E; Cuomo A; Ascierto PA; Cascella M
    J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tocilizumab in addition to standard of care in the management of COVID-19: a meta-analysis of RCTs.
    Mutua V; Henry BM; Csefalvay CV; Cheruiyot I; Vikse J; Lippi G; Bundi B; Mong'are N
    Acta Biomed; 2022 Mar; 93(1):e2022014. PubMed ID: 35315395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis.
    Aziz M; Haghbin H; Abu Sitta E; Nawras Y; Fatima R; Sharma S; Lee-Smith W; Duggan J; Kammeyer JA; Hanrahan J; Assaly R
    J Med Virol; 2021 Mar; 93(3):1620-1630. PubMed ID: 32918755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study.
    Sánchez-Conde M; Vizcarra P; Pérez-García JM; Gion M; Martialay MP; Taboada J; Alonso-Fernández A; Sampayo-Cordero M; Malfettone A; Tena I; Torre S; Llombart-Cussac A; Cortés J
    Int J Infect Dis; 2022 Oct; 123():97-103. PubMed ID: 35987472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review.
    Roomi S; Ullah W; Ahmed F; Farooq S; Sadiq U; Chohan A; Jafar M; Saddique M; Khanal S; Watson R; Boigon M
    J Med Internet Res; 2020 Sep; 22(9):e21758. PubMed ID: 32784192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Observational study on off-label use of tocilizumab in patients with severe COVID-19.
    Albertini L; Soletchnik M; Razurel A; Cohen J; Bidegain F; Fauvelle F; Safrano G; Piquet J; Maurer C; Goldgran-Toledano D
    Eur J Hosp Pharm; 2021 Jan; 28(1):22-27. PubMed ID: 32912961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study.
    Broman N; Feuth T; Vuorinen T; Valtonen M; Hohenthal U; Löyttyniemi E; Hirvioja T; Jalava-Karvinen P; Marttila H; Nordberg M; Oksi J
    Clin Microbiol Infect; 2022 Jun; 28(6):844-851. PubMed ID: 35259529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation.
    Menzella F; Fontana M; Salvarani C; Massari M; Ruggiero P; Scelfo C; Barbieri C; Castagnetti C; Catellani C; Gibellini G; Falco F; Ghidoni G; Livrieri F; Montanari G; Casalini E; Piro R; Mancuso P; Ghidorsi L; Facciolongo N
    Crit Care; 2020 Sep; 24(1):589. PubMed ID: 32993751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).
    Colaneri M; Bogliolo L; Valsecchi P; Sacchi P; Zuccaro V; Brandolino F; Montecucco C; Mojoli F; Giusti EM; Bruno R; The Covid Irccs San Matteo Pavia Task Force
    Microorganisms; 2020 May; 8(5):. PubMed ID: 32397399
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes.
    Al-Baadani A; Eltayeb N; Alsufyani E; Albahrani S; Basheri S; Albayat H; Batubara E; Ballool S; Al Assiri A; Faqihi F; Musa AB; Robert AA; Alsherbeeni N; Elzein F
    J Infect Public Health; 2021 Aug; 14(8):1021-1027. PubMed ID: 34153727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
    Galván-Román JM; Rodríguez-García SC; Roy-Vallejo E; Marcos-Jiménez A; Sánchez-Alonso S; Fernández-Díaz C; Alcaraz-Serna A; Mateu-Albero T; Rodríguez-Cortes P; Sánchez-Cerrillo I; Esparcia L; Martínez-Fleta P; López-Sanz C; Gabrie L; Del Campo Guerola L; Suárez-Fernández C; Ancochea J; Canabal A; Albert P; Rodríguez-Serrano DA; Aguilar JM; Del Arco C; de Los Santos I; García-Fraile L; de la Cámara R; Serra JM; Ramírez E; Alonso T; Landete P; Soriano JB; Martín-Gayo E; Fraile Torres A; Zurita Cruz ND; García-Vicuña R; Cardeñoso L; Sánchez-Madrid F; Alfranca A; Muñoz-Calleja C; González-Álvaro I;
    J Allergy Clin Immunol; 2021 Jan; 147(1):72-80.e8. PubMed ID: 33010257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2.
    Saffo Z; Guo W; Springer K; Maksimowicz-McKinnon K; Kak V; McKinnon JE; Bhargava P
    J Osteopath Med; 2021 Jul; 121(8):705-714. PubMed ID: 34237804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefits of Tocilizumab in patients with a severe form of SARS-CoV-2 infection: Experience of the intensive care unit of the Mohammed VI university hospital, Oujda.
    El Rhalete A; Rhazi I; Bensaid A; Diass S; Kaouini A; Ounci E; Abdi M; Maarad M; Babouh C; Alami Z; Abda N; Bkiyer H; Housni B
    Ann Med Surg (Lond); 2021 Jul; 67():102514. PubMed ID: 34221397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.
    Rossotti R; Travi G; Ughi N; Corradin M; Baiguera C; Fumagalli R; Bottiroli M; Mondino M; Merli M; Bellone A; Basile A; Ruggeri R; Colombo F; Moreno M; Pastori S; Perno CF; Tarsia P; Epis OM; Puoti M;
    J Infect; 2020 Oct; 81(4):e11-e17. PubMed ID: 32652164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.